Oncology research focuses on the treatment and prevention of cancer in the body and blood. These clinical trials may evaluate new medications, treatments or interventions for cancer, cancer prevention and methods to reduce side effects from treatment.

Common Types of Cancer:

•    Lung cancer
•    Breast cancer
•    Prostate cancer
•    Colorectal cancer
•    Pancreatic cancer
•    Hematologic (blood) cancers such as lymphoma and leukemia

To learn more about participating in a clinical trial, please contact us at 

1-800-836-0388 or clinical.research@guthrie.org

 

 

Title: * Flatiron Health Parent Protocol for Prospective Real World Studies (PrwS Parent Protocol - FH-PrwS-07)

** Molecular Residual Disease in Solid Tumors: A Prospective Study to Collect Clinical Data and Biospecimens to Support Discovery and Development of Cancer Biomarkers (Substudy Number: FH-PrwS-07-002)
Department: Oncology
Diagnosis: Cancer - Oncology
Principal Investigator:

Macfie MD, Rebekah

Sponsors: Flatiron Health, Inc.
Details (Identifier #): NCT06605404
Title: A Phase 2, Open-Label, Randomized, Global Study of Two Telisotuzumab Vedotin Regimens in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer
Department: Oncology
Diagnosis: Cancer - Lung
Principal Investigator:

Poulose MD, Joyson

Sponsors: AbbVie
Details (Identifier #): NCT06568939
Title: A Phase 3 Randomized, Double-Blind, Active-Controlled
Study of Palazestrant with Ribociclib Versus Letrozole with
Ribociclib for the First-Line Treatment of ER+, HER2
Advanced Breast Cancer (OPERA-02)
Department: Oncology
Diagnosis: Cancer - Breast
Principal Investigator:

Poulose MD, Joyson

Sponsors: Olema Pharmaceuticals, Inc.
Details (Identifier #): NCT07085767
Title: A Phase 3 Randomized, Open-Label Study of OP-1250 Monotherapy vs Standard of Care for the Treatment of ER+, HER2- Advanced or Metastatic Breast Cancer Following Endocrine and CDK 4/6 Inhibitor Therapy (OPERA-01)
Department: Oncology
Diagnosis: Cancer - Breast
Principal Investigator:

Poulose MD, Joyson

Sponsors: Olema Pharmaceuticals, Inc.
Details (Identifier #): NCT06016738
Title: A Randomized, Double-blinded, Multicenter, Phase III Clinical Study of HLX22 (Recombinant Humanized Anti-HER2 Monoclonal Antibody Injection) in Combination with Trastuzumab and Chemotherapy (XELOX) versus Trastuzumab and Chemotherapy (XELOX) with or without Pembrolizumab for the First Line Treatment of Locally Advanced or Metastatic Gastroesophageal Junction and Gastric Cancer
Department: Oncology
Diagnosis: Cancer - Oncology
Principal Investigator:

Poulose MD, Joyson

Sponsors: Shanghai Henlius Biotech, Inc.
Details (Identifier #): NCT06532006
Title: A032102, PREcision DIagnostics in prostate Cancer Treatment (PREDICT)
Department: Oncology
Diagnosis: Cancer - Oncology
Sponsors: ALLIANCE
Details (Identifier #): NCT06632977
Title: ALLIANCE A222004:
A RANDOMIZED PHASE III TRIAL OF OLANZAPINE VERSUS MEGESTROL ACETATE FOR CANCER-ASSOCIATED ANOREXIA
Department: Oncology
Diagnosis: Cancer - Oncology
Principal Investigator:

Poulose MD, Joyson

Sponsors: ALLIANCE
Title: ASCENT A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy
Department: Oncology
Diagnosis: Cancer - Breast
Principal Investigator:

Poulose MD, Joyson

Sponsors: Gilead Sciences
Details (Identifier #): NCT05633654
Title: CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next-Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients with ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease
Department: Oncology
Diagnosis: Cancer - Breast
Principal Investigator:

Poulose MD, Joyson

Sponsors: Astra Zeneca Pharmaceutical, LP
Details (Identifier #): NCT04964934
Title: EA5182: Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
Department: Oncology
Diagnosis: Cancer - Lung
Principal Investigator:

Poulose MD, Joyson

Sponsors: ECOG-ACRIN Cancer Research Group
Details (Identifier #): NCT04181060
Showing 1-10 of 26 Results